Meyer Handelman Co. Sells 11,350 Shares of Pfizer Inc. $PFE

Key Points

• Meyer Handelman Co. has decreased its stake in Pfizer Inc. by **0.9%**, selling **11,350 shares** and holding **1,280,447 shares** valued at **$31,038,000** as of the last quarter.
• Pfizer reported earnings of **$0.78 per share**, surpassing analysts' expectations of **$0.58**, with a revenue increase of **10.3%** year-over-year, amounting to **$14.65 billion**.
• As of now, Pfizer shares have a consensus rating of **"Hold"** with an average price target of **$28.12**, after some analysts raised their price objectives recently.

Meyer Handelman Co. lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 0.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,280,447 shares of the biopharmaceutical company's stock after selling 11,350 shares during the quarter. Meyer Handelman Co.'s holdings in Pfizer were worth $31,038,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Bessemer Group Inc. increased its position in shares of Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after purchasing an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK raised its position in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after buying an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp purchased a new position in Pfizer in the first quarter worth $8,283,000. Westbourne Investments Inc. purchased a new position in Pfizer in the first quarter worth $2,411,000. Finally, Bourne Lent Asset Management Inc. increased its stake in Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock valued at $927,000 after acquiring an additional 18,200 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

PFE stock opened at $23.61 on Friday. The stock has a market capitalization of $134.25 billion, a price-to-earnings ratio of 12.56, a PEG ratio of 0.78 and a beta of 0.55. The firm's 50-day moving average price is $24.57 and its two-hundred day moving average price is $24.16. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the business posted $0.60 earnings per share. Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on PFE shares. Bank of America upped their price objective on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Berenberg Bank reduced their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday, September 20th. Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Finally, Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.